Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4
Astellas Pharma Inc. co-promotes telmisartan underneath the trademark Micardisî, Bayer HealthCare promote telmisartan under the pour scorn next to outshine through Kinzalmonoî, Kinzalkombî (combination close hydrochlorothiazide), and Pritorî and PritorPlusî (combination with hydrochlorothiazide) surrounded by souk across Europe. Pritorî, and PritorPlusî be also market via GlaxoSmithKline in select markets.
The promoter of the ONTARGETî Trial Programme is Boehringer Ingelheim; co-funders in selected rural area be Bayer HealthCare and GlaxoSmithKline.
Boehringer Ingelheim The Boehringer Ingelheim range is one of the world’s 20 ascendant pharmaceutical joint endeavour. Headquartered in Ingelheim, Germany, it operate worldwide with 135 affiliate in 47 countries and 39,800 article. Since it be found in 1885, the family-owned company have be committed to research, nascent, productivity and marketing original products of soaring energizing appeal in favour of human and veterinary prescription.
In 2007, Boehringer Ingelheim send off web sale of 10.9 billion euro while outlay one fifth of net sales in its largest company segment Prescription Medicines on research and step up.
Related links: Boehringer Ingelheim wring pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals open-air the U.S. only)Micardisî website (for Healthcare Professionals outside the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular measures in high-risk patients remorseless to angiotensin-converting enzyme inhibitors: a randomized controlled tribunal. Lancet Published online 31 August 2008.
2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.
3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high menace for vascular events. N Eng J Med 2008; 358(15):1547-59.
Lupin expressly disavow any activity to update the information presented in this release Zocor(R) is a register trademark of MERCK & CO., Inc.
5.Matchar DB, et al. Systematic Review: Comparative worth of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for excess peak hypertension.
Ann Intern Med 2008; 148:16-29.
The study is published in the Journal of the American Medical Association (JAMA).
7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A wholesale costing of mortality and disability from disease, injury, and risk factor in 1990 and projected to 2020.
Cambridge; Harvard University Press 2001.
9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37:1583-1633.
Boehringer Ingelheim
online pharmacy generic glucotrol now
Press to learn here more 20 mg
news lotensin blog